Targeted Therapies in Kidney Cancer

2015 ◽  
pp. 197-210
Author(s):  
Amparo Sánchez Gastaldo ◽  
Aránzazu González del Alba ◽  
Ignacio Durán
Keyword(s):  
Kidney Cancer ◽  
Targeted Therapies

New targeted therapies in kidney cancer

2021 ◽  
Author(s):  
Karl Mayrhofer ◽  
Dora Niedersüß-Beke
Keyword(s):  
Kidney Cancer ◽  
Targeted Therapies

Genetic basis of kidney cancer: a model for developing molecular-targeted therapies

2007 ◽  
Vol 99 (5b) ◽  
pp. 1223-1229 ◽  
Author(s):  
Manish A. Vira ◽  
Kristian R. Novakovic ◽  
Peter A. Pinto ◽  
W. Marston Linehan
Keyword(s):  
Kidney Cancer ◽  
Targeted Therapies ◽  
Genetic Basis ◽  
Molecular Targeted Therapies

Kidney cancer: Experience of Centro Oncologico Buenos Aires (COBA) with immunotherapy (It) and targeted therapies (TT).

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. e15024-e15024
Author(s):  
A. P. Hunis ◽  
L. A. Reuter ◽  
M. Hunis ◽  
A. Deves
Keyword(s):  
Kidney Cancer ◽  
Targeted Therapies ◽  
Buenos Aires ◽  
Cancer Experience

Targeted therapies for kidney cancer in urologic practice

2007 ◽  
Vol 25 (5) ◽  
pp. 420-432 ◽  
Author(s):  
Naomi B. Haas ◽  
Robert G. Uzzo
Keyword(s):  
Kidney Cancer ◽  
Targeted Therapies

scholarly journals Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study

BMC Cancer ◽  
2016 ◽  
Vol 16 (1) ◽  
Author(s):  
Nuria Lainez ◽  
Jesús García-Donas ◽  
Emilio Esteban ◽  
Javier Puente ◽  
M. Isabel Sáez ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Kidney Cancer ◽  
Targeted Therapies

scholarly journals New surgical horizons: the role of cytoreductive nephrectomy for metastatic kidney cancer

2012 ◽  
Vol 1 (2S) ◽  
Author(s):  
Ricardo A. Rendon
Keyword(s):  
Renal Cell Carcinoma ◽  
Kidney Cancer ◽  
Metastatic Disease ◽  
Targeted Therapies ◽  
Standard Treatment ◽  
Advanced Disease ◽  
Locally Advanced ◽  
Cytoreductive Nephrectomy ◽  
Urologic Malignancy

Renal cell carcinoma is the most lethal urologic malignancy. Up to 30% of patients with kidney cancer have metastatic disease and 30% of those treatedfor local or locally advanced disease will progress to metastases. Radical nephrectomy is the standard treatment for the management of nondisseminated kidney cancer, but the role of cytoreductive nephrectomy for patients with metastatic disease is controversial. In this paper, the rationale for cytoreductivenephrectomy is described and the currently available evidence for andagainst it is evaluated. The different approaches to defining prognostic factorsto select which patients will benefit from cytoreductive nephrectomy willalso be described. Finally, the role of cytoreductive nephrectomy in the eraof new targeted therapies is discussed.

The Genetic Basis of Kidney Cancer and Implications for Targeted Therapies

2012 ◽  
pp. 3-25
Author(s):  
Laura S. Schmidt ◽  
Ramaprasad Srinivasan ◽  
W. Marston Linehan
Keyword(s):  
Kidney Cancer ◽  
Targeted Therapies ◽  
Genetic Basis

ASCO21 – Key Updates for Kidney Cancer Patients

2021 ◽  
Vol 19 (2) ◽  
Author(s):  
Neil Shah
Keyword(s):  
Cancer Treatment ◽  
Cancer Patients ◽  
Annual Meeting ◽  
Kidney Cancer ◽  
Targeted Therapies

Over the last decade, novel immunotherapies and targeted therapies have revolutionized the kidney cancer treatment landscape. ASCO Annual Meeting, 2021, was yet another success against this battle, and in this commentary, we will focus on a few critical abstracts presented at the meeting pertinent to kidney cancer.

scholarly journals Survival outcomes for advanced kidney cancer patients in the era of targeted therapies

2018 ◽  
Vol 6 (9) ◽  
pp. 165-165 ◽  
Author(s):  
Arpit Rao ◽  
Charles Wiggins ◽  
Richard C. Lauer
Keyword(s):  
Cancer Patients ◽  
Kidney Cancer ◽  
Targeted Therapies ◽  
Survival Outcomes
Sign in / Sign up

Export Citation Format

Share Document